- Home
- BRID vs AGEN Comparison
BRID vs AGEN Comparison
Compare BRID & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRID
- AGEN
- Stock Information
- Founded
- BRID 1932
- AGEN 1994
- Country
- BRID United States
- AGEN United States
- Employees
- BRID N/A
- AGEN N/A
- Industry
- BRID Specialty Foods
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRID Consumer Staples
- AGEN Health Care
- Exchange
- BRID Nasdaq
- AGEN Nasdaq
- Market Cap
- BRID 87.3M
- AGEN 96.2M
- IPO Year
- BRID N/A
- AGEN 2000
- Fundamental
- Price
- BRID $10.41
- AGEN $3.48
- Analyst Decision
- BRID
- AGEN Buy
- Analyst Count
- BRID 0
- AGEN 3
- Target Price
- BRID N/A
- AGEN $10.50
- AVG Volume (30 Days)
- BRID 2.3K
- AGEN 419.4K
- Earning Date
- BRID 03-07-2025
- AGEN 03-13-2025
- Dividend Yield
- BRID N/A
- AGEN N/A
- EPS Growth
- BRID N/A
- AGEN N/A
- EPS
- BRID N/A
- AGEN N/A
- Revenue
- BRID $231,734,000.00
- AGEN $160,427,000.00
- Revenue This Year
- BRID N/A
- AGEN N/A
- Revenue Next Year
- BRID N/A
- AGEN $36.13
- P/E Ratio
- BRID N/A
- AGEN N/A
- Revenue Growth
- BRID N/A
- AGEN 59.00
- 52 Week Low
- BRID $7.77
- AGEN $2.50
- 52 Week High
- BRID $14.69
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- BRID 51.47
- AGEN 58.60
- Support Level
- BRID $10.20
- AGEN $3.08
- Resistance Level
- BRID $10.50
- AGEN $3.29
- Average True Range (ATR)
- BRID 0.18
- AGEN 0.26
- MACD
- BRID -0.09
- AGEN 0.05
- Stochastic Oscillator
- BRID 42.47
- AGEN 80.36
About BRID Bridgford Foods Corporation
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are processing and distribution of frozen products, and processing and distribution of snack food products. It includes products such as biscuits, bread dough items, roll dough items, dry sausage products, and beef jerky. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. It derives a majority of its revenue from snack food products.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).